Our findings demonstrate that DUSP9 enhances resistance to sorafenib via SCD‐dependent lipid metabolism, suggesting that the DUSP9–SCD axis may dictate treatment response in a subset of HCC patients. The gene discussed is DUSP9; the disease is hepatocellular carcinoma.